article · Journal of Advances in Medical and Pharmaceutical Sciences
Building upon our recent finding that the biopolymer matrix of green-synthesized silver nanoparticles (AgNPs) dictates their exceptional safety (LD50 > 5000 mg/kg) and antimalarial efficacy, this study employed a computational framework to de-convolute the molecular identity of this critical passivation layer. While our previous in vivo work hypothesized that the organic capping matrix facilitates endocytic uptake and mitigates toxicity, the specific ligand-receptor interactions remained undefined. In the present study, we utilized Density Functional Theory (DFT), ADMET profiling, and MM-GBSA calculations to interrogate the primary Gongronema latifolium phytochemicals constituting the nanoparticle surface. DFT analysis confirmed the structural hypothesis: Sarsasapogenin served as the rigid, chemically inert steric stabilizer (\(\Delta\)Egap= 8.83 eV), explaining the protective masking observed previously in XRD, while Tannic Acid (\(\Delta\)Egap = 2.91 eV) drives the redox activity. Pharmacokinetic screening identified Cinchonidine as the bioactive lead, with 94.5% oral bioavailability and blood-brain barrier permeability. Crucially, molecular docking revealed that this biopolymer complex does not merely act via general oxidative stress; Cinchonidine selectively targets Plasmodium falciparum Dihydrofolate Reductase (PfDHFR; \(\Delta\)Gbind = -48.85 kcal/mol) while sparing Lactate Dehydrogenase (PfLDH). These findings provide the molecular validation for our prior empirical observations, bridging the gap between murine safety signals and human therapeutic mechanisms.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.9734/jamps/2026/v28i3850
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.